S. Francis

发表

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Axel Hoos, Alessandro Testori, Axel Hauschild, 2011, The New England journal of medicine.

Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.

M. Dowsett, S. Ebbs, J. Salter, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Andreas Hochhaus, R. Collins, H. Kantarjian, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in combination with gemcitabine (GEM) in patients (pts) with advanced pancreatic cancer.

P. Bycott, J. Spano, B. Hee, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: One-year results of CA180034

H. Kantarjian, P. Rousselot, A. Hochhaus, 2007 .

Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast Cancer

M. Dowsett, S. Ebbs, J. Salter, 2006, Clinical Cancer Research.

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.

M. Dowsett, S. Ebbs, J. Blohmer, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dasatinib (SPRYCEL®) 50mg or 70mg BID Versus 100mg or 140mg QD in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Resistant or Intolerant to Imatinib: Results of the CA180-034 Study.

H. Kantarjian, P. Rousselot, A. Hochhaus, 2006 .

Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.

M. Dowsett, S. Ebbs, J. Salter, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

F. Hodi, S. O’Day, T. Guthrie, 2016, Journal of Immunotherapy for Cancer.

Effect of ipilimumab at 10 mg/kg on disease control in patients (pts) with M1c-stage melanoma in relation to baseline lactate dehydrogenase (LDH) levels.

D. Schadendorf, M. Smylie, B. Neyns, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Four-Year Survival Update for Metastatic Melanoma (MM) Patients (PTS) Treated with Ipilimumab (IPI) + Dacarbazine (DTIC) on Phase 3 Study CA184-024

J. Wolchok, A. Testori, C. Garbe, 2012 .

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.

N. Johnson, P. Zinzani, J. Kuruvilla, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A single-arm, open-label, phase II study to evaluate the safety of vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic melanoma (MM).

F. Hodi, T. Guthrie, A. Salama, 2015 .

CA184-161: A phase I/II trial of vemurafenib and ipilimumab in patients with BRAF V600 mutation-positive metastatic melanoma.

J. Wolchok, A. Ribas, F. Hodi, 2012 .

Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial

N. Johnson, A. Santoro, P. Zinzani, 2018, Blood.

1105PVEMURAFENIB FOR BRAF V600 MUTATED ADVANCED MELANOMA: RESULTS OF TREATMENT BEYOND PROGRESSION.

Y. S. Kim, Su Jin Lee, J. Utikal, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EXTENDED FOLLOW‐UP FROM THE PHASE 2 CHECKMATE 436 STUDY

N. Johnson, A. Santoro, P. Zinzani, 2021, Hematological Oncology.

Nivolumab and brentuximab vedotin (BV)-based, response‐adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis.

K. Kelly, T. Leblanc, M. Puhlmann, 2020 .

Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Mediastinal Gray Zone Lymphoma: Primary Efficacy and Safety Analysis of the Phase 2 CheckMate 436 Study

K. Savage, A. Santoro, S. Ferrari, 2020, Blood.

Safety of ipilimumab in patients (pts) with untreated, advanced melanoma alive beyond 2 years: Results from a phase III study.

J. Wolchok, C. Garbe, C. Robert, 2012 .

Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma.

J. Wolchok, J. Weber, L. Thomas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.